Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07710534 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Start date changed from estimate of Sep 30, 2026 to Sep 16, 2026
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints: details revised at 6 of 10 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center randomized phase 2 open-label clinical trial.
Trial Details
NCT Number NCT07710534
Lead Sponsor Virginia Commonwealth University
Conditions
(from sponsor)		 Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
Related terms Leukemia, Myeloid, Acute
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov